Philippe Rougier
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
Papers in
- Oncology 101
- Colorectal Cancer Treatments and Studies 70
- Pancreatic and Hepatic Oncology Research 20
- Cancer Treatment and Pharmacology 16
-
- Gastric Cancer Management and Outcomes 30
- Co-authors
- Eric Van Cutsem (31 shared papers)Bernard Nordlinger (20 shared papers)Claus-Henning Köhne (5 shared papers)Michael Schlichting (4 shared papers)Gunnar Folprecht (9 shared papers)Christophe Penna (14 shared papers)G. Bodoky (6 shared papers)Michel Ducreux (14 shared papers)
In The Last Decade
Philippe Rougier
125 papers receiving 21.9k citations
Philippe Rougier's Hit Papers
Peers
Comparison fields: 5 of 136
- Hepatology 6.6k
- Oncology 17.4k
- Pathology and Forensic Medicine 4.1k
- Pulmonary and Respiratory Medicine 7.4k
- Cancer Research 2.7k
Countries citing papers authored by Philippe Rougier
This map shows the geographic impact of Philippe Rougier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Rougier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Rougier more than expected).
Fields of papers citing papers by Philippe Rougier
This network shows the impact of papers produced by Philippe Rougier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Rougier. The network helps show where Philippe Rougier may publish in the future.
Co-authors
The 25 scholars most cited alongside Philippe Rougier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 128 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Hit paper breakdown → | 2009 | 2902 |
| 2 | KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer Hit paper breakdown → | 2006 | 1729 |
| 3 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1715 |
| 4 | Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Hit paper breakdown → | 2011 | 1441 |
| 5 | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Hit paper breakdown → | 2008 | 1396 |
| 6 | KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Hit paper breakdown → | 2008 | 1141 |
| 7 | Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Hit paper breakdown → | 2013 | 853 |
| 8 | Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. Hit paper breakdown → | 1998 | 789 |
| 9 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Hit paper breakdown → | 1998 | 786 |
| 10 | Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer Hit paper breakdown → | 2015 | 578 |
| 11 | Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer Hit paper breakdown → | 2009 | 529 |
| 12 | Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases Hit paper breakdown → | 2005 | 527 |
| 13 | Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial Hit paper breakdown → | 2009 | 487 |
| 14 | Long-term results and prognostic factors in patients with differentiated thyroid carcinoma Hit paper breakdown → | 1985 | 461 |
| 15 | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials Hit paper breakdown → | 2012 | 447 |
| 16 | 2006 | 433 | |
| 17 | 1998 | 404 | |
| 18 | 2012 | 385 | |
| 19 | 2006 | 381 | |
| 20 | Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus Hit paper breakdown → | 2015 | 376 |
About Philippe Rougier
Philippe Rougier is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Hepatology and Epidemiology, having authored 128 papers that have together received 22.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (70 papers), Gastric Cancer Management and Outcomes (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Pancreatic and Hepatic Oncology Research (20 papers), Neuroendocrine Tumor Research Advances (20 papers), Genetic factors in colorectal cancer (18 papers), Neuroblastoma Research and Treatments (17 papers) and Cancer Treatment and Pharmacology (16 papers). The work is most often cited by research in Hepatology (6.6k citations), Oncology (17.4k citations), Pathology and Forensic Medicine (4.1k citations), Pulmonary and Respiratory Medicine (7.4k citations) and Cancer Research (2.7k citations). Philippe Rougier has collaborated with scholars based in France, Belgium and Germany. Frequent co-authors include Eric Van Cutsem, Bernard Nordlinger, Claus-Henning Köhne, Michael Schlichting, Gunnar Folprecht, Christophe Penna, G. Bodoky, Michel Ducreux, Pierre Laurent‐Puig and Sabine Tejpar. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, The Lancet Oncology, Cancer and Digestive and Liver Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.